MesoPher cell therapy increases 2-year RFS rate in resected pancreatic cancer by 50%; publication of phase II results in Journal of Clinical Oncology and Orphan Designation granted by FDA & EMA

25 Sep 2024

‘s-HERTOGENBOSCH, the Netherlands; September 25, 2024. Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, announces publication of the results of a phase II trial in resected pancreatic cancer (REACTIVE) in the Journal of Clinical Oncology (JCO).

Highlights from the REACTIVE trial in resected pancreatic cancer:

The phase II trial, including 38 patients with resected pancreatic cancer who had completed standard-of-care chemotherapy, met the primary endpoint demonstrating a clinically significant increase in 2-year recurrence-free survival of 64% compared to an expected 40%. This was accompanied with only low grade side effects.

The 2-year overall survival rate was 83%. Translational

Read more »